{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:36:06Z","timestamp":1781642166245,"version":"3.54.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T00:00:00Z","timestamp":1563321600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T00:00:00Z","timestamp":1563321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5913-9","type":"journal-article","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T14:03:18Z","timestamp":1563372198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1237-331X","authenticated-orcid":false,"given":"J.","family":"Chantharasamee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Poungvarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Danchaivijitr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Techawatanawanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,17]]},"reference":[{"issue":"5","key":"5913_CR1","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1002\/ijc.27711","volume":"132","author":"F Bray","year":"2013","unstructured":"Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132(5):1133\u201345.","journal-title":"Int J Cancer"},{"issue":"9","key":"5913_CR2","first-page":"2892","volume":"5","author":"A Midha","year":"2015","unstructured":"Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892.","journal-title":"Am J Cancer Res"},{"issue":"6","key":"5913_CR3","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.jtho.2017.02.001","volume":"12","author":"N Guibert","year":"2017","unstructured":"Guibert N, Barlesi F, Descourt R, L\u00e9na H, Besse B, Beau-Faller M, et al. Characteristics and outcomes of patients with lung cancer harboring multiple molecular alterations: results from the IFCT study biomarkers France. J Thorac Oncol. 2017;12(6):963\u201373.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"5913_CR4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1093\/annonc\/mds214","volume":"24","author":"A Inoue","year":"2012","unstructured":"Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin\u2013paclitaxel for chemo-na\u00efve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2012;24(1):54\u20139.","journal-title":"Ann Oncol"},{"issue":"10","key":"5913_CR5","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, et al. Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947\u201357.","journal-title":"N Engl J Med"},{"issue":"2","key":"5913_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","volume":"15","author":"Y-L Wu","year":"2014","unstructured":"Wu Y-L, Zhou C, Hu C-P, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213\u201322.","journal-title":"Lancet Oncol"},{"issue":"2","key":"5913_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","volume":"16","author":"JC-H Yang","year":"2015","unstructured":"Yang JC-H, Wu Y-L, Schuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-lung 3 and LUX-lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16(2):141\u201351.","journal-title":"Lancet Oncol"},{"issue":"10026","key":"5913_CR8","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","volume":"387","author":"F Barlesi","year":"2016","unstructured":"Barlesi F, Mazieres J, Merlio J-P, Debieuvre D, Mosser J, Lena H, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French cooperative thoracic intergroup (IFCT). Lancet. 2016;387(10026):1415\u201326.","journal-title":"Lancet"},{"issue":"8","key":"5913_CR9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","volume":"12","author":"C Zhou","year":"2011","unstructured":"Zhou C, Wu Y-L, Chen G, Feng J, Liu X-Q, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735\u201342.","journal-title":"Lancet Oncol"},{"issue":"4","key":"5913_CR10","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jtho.2015.12.107","volume":"11","author":"B Klughammer","year":"2016","unstructured":"Klughammer B, Brugger W, Cappuzzo F, Ciuleanu T, Mok T, Reck M, et al. Examining treatment outcomes with Erlotinib in patients with advanced non\u2013small cell lung cancer whose Tumors Harbor uncommon EGFR mutations. J Thorac Oncol. 2016;11(4):545\u201355.","journal-title":"J Thorac Oncol"},{"issue":"31","key":"5913_CR11","doi-asserted-by":"publisher","first-page":"4336","DOI":"10.1038\/onc.2008.71","volume":"27","author":"Z Chen","year":"2008","unstructured":"Chen Z, Feng J, Saldivar J, Gu D, Bockholt A, Sommer S. EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids. Oncogene. 2008;27(31):4336.","journal-title":"Oncogene"},{"issue":"7","key":"5913_CR12","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","volume":"16","author":"JC Yang","year":"2015","unstructured":"Yang JC, Sequist LV, Geater SL, Tsai C-M, Mok TSK, Schuler M, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-lung 2, LUX-lung 3, and LUX-lung 6. Lancet Oncol. 2015;16(7):830\u20138.","journal-title":"Lancet Oncol"},{"issue":"1","key":"5913_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.cllc.2017.05.016","volume":"19","author":"S Pilotto","year":"2018","unstructured":"Pilotto S, Rossi A, Vaval\u00e0 T, Follador A, Tiseo M, Galetta D, et al. Outcomes of first-generation EGFR-TKIs against non-small-cell lung cancer harboring uncommon EGFR mutations: a post hoc analysis of the BE-POSITIVE study. Clin Lung Cancer. 2018;19(1):93\u2013104.","journal-title":"Clin Lung Cancer"},{"issue":"5","key":"5913_CR14","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1097\/JTO.0000000000000492","volume":"10","author":"Z Lohinai","year":"2015","unstructured":"Lohinai Z, Hoda MA, Fabian K, Ostoros G, Raso E, Barbai T, et al. Distinct epidemiology and clinical consequence of classic versus rare EGFR mutations in lung adenocarcinoma. J Thorac Oncol. 2015;10(5):738\u201346.","journal-title":"J Thorac Oncol"},{"key":"5913_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.lungcan.2016.01.018","volume":"96","author":"J Xu","year":"2016","unstructured":"Xu J, Jin B, Chu T, Dong X, Yang H, Zhang Y, et al. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: a real-world study in China. Lung Cancer. 2016;96:87\u201392.","journal-title":"Lung Cancer"},{"issue":"6","key":"5913_CR16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.21147\/j.issn.1000-9604.2017.06.09","volume":"29","author":"J Shi","year":"2017","unstructured":"Shi J, Yang H, Jiang T, Li X, Zhao C, Zhang L, et al. Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy. Chin J Cancer Res. 2017;29(6):543.","journal-title":"Chin J Cancer Res"},{"issue":"5","key":"5913_CR17","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.cllc.2015.11.004","volume":"17","author":"P Ulivi","year":"2016","unstructured":"Ulivi P, Chiadini E, Dazzi C, Dubini A, Costantini M, Medri L, et al. Nonsquamous, non-small-cell lung cancer patients who carry a double mutation of EGFR, EML4-ALK or KRAS: frequency, clinical-pathological characteristics, and response to therapy. Clin Lung Cancer. 2016;17(5):384\u201390.","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"5913_CR18","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.jtho.2016.09.001","volume":"12","author":"MB Barnet","year":"2017","unstructured":"Barnet MB, O\u2019Toole S, Horvath LG, Selinger C, Yu B, Ng CC, et al. EGFR\u2013co-mutated advanced NSCLC and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2017;12(3):585\u201390.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"5913_CR19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3892\/mco.2014.455","volume":"3","author":"T Oikawa","year":"2015","unstructured":"Oikawa T, Ohira T, Otani K, Hagiwara M, Konaka C, Ikeda N. Clinical usefulness of gefitinib for non-small-cell lung cancer with a double epidermal growth factor receptor mutation. Mol Clin Oncol. 2015;3(2):329\u201333.","journal-title":"Mol Clin Oncol"},{"issue":"1","key":"5913_CR20","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/annonc\/mdt418","volume":"25","author":"M Beau-Faller","year":"2013","unstructured":"Beau-Faller M, Prim N, Ruppert A-M, Nanni-Metellus I, Lacave R, Lacroix L, et al. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol. 2013;25(1):126\u201331.","journal-title":"Ann Oncol"},{"key":"5913_CR21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.lungcan.2017.04.016","volume":"109","author":"GM O\u2019Kane","year":"2017","unstructured":"O\u2019Kane GM, Bradbury PA, Feld R, Leighl NB, Liu G, Pisters K-M, et al. Uncommon EGFR mutations in advanced non-small cell lung cancer. Lung Cancer. 2017;109:137\u201344.","journal-title":"Lung Cancer"},{"issue":"10","key":"5913_CR22","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1097\/JTO.0000000000000221","volume":"9","author":"MD Hellmann","year":"2014","unstructured":"Hellmann MD, Reva B, Yu H, Rusch VW, Rizvi NA, Kris MG, et al. Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib. J Thorac Oncol. 2014;9(10):e73\u2013e4.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"5913_CR23","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1158\/1078-0432.CCR-10-3408","volume":"17","author":"J.-Y. Wu","year":"2011","unstructured":"Wu J-Y, Yu C-J, Chang Y-C, Yang JC-H, Shih J-Y, Yang P-C. Effectiveness of tyrosine kinase inhibitors on uncommon epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res. 2011;17:3812-21.","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"5913_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11523-016-0455-4","volume":"12","author":"X Zhu","year":"2017","unstructured":"Zhu X, Bai Q, Lu Y, Qi P, Ding J, Wang J, et al. Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I: a retrospective analysis and literature review. Target Oncol. 2017;12(1):81\u20138.","journal-title":"Target Oncol"},{"issue":"8","key":"5913_CR25","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1158\/1535-7163.MCT-08-1219","volume":"8","author":"I. Y.-S. Tam","year":"2009","unstructured":"Tam IY, Leung EL, Tin VP, Chua DT, Sihoe AD, Cheng LC, Chung LP, Wong MP. Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations. Mol Cancer Ther. 2009;8:2142-51.","journal-title":"Molecular Cancer Therapeutics"},{"issue":"1","key":"5913_CR26","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/JTO.0b013e3182781e35","volume":"8","author":"S Kobayashi","year":"2013","unstructured":"Kobayashi S, Canepa HM, Bailey AS, Nakayama S, Yamaguchi N, Goldstein MA, et al. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2013;8(1):118\u201322.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"5913_CR27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.21147\/j.issn.1000-9604.2017.01.03","volume":"29","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Wang Z, Hao X, Hu X, Wang H, Wang Y, et al. Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations. Chin J Cancer Res. 2017;29(1):18.","journal-title":"Chin J Cancer Res"},{"key":"5913_CR28","doi-asserted-by":"publisher","first-page":"6137","DOI":"10.2147\/OTT.S118071","volume":"9","author":"J-Y Wu","year":"2016","unstructured":"Wu J-Y, Shih J-Y. Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer. Onco Targets Ther. 2016;9:6137.","journal-title":"Onco Targets Ther"},{"issue":"10","key":"5913_CR29","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1158\/1078-0432.CCR-06-3043","volume":"13","author":"E Massarelli","year":"2007","unstructured":"Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non\u2013small-cell lung cancer. Clin Cancer Res. 2007;13(10):2890\u20136.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"5913_CR30","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S1470-2045(08)70206-7","volume":"9","author":"H Linardou","year":"2008","unstructured":"Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008;9(10):962\u201372.","journal-title":"Lancet Oncol"},{"issue":"5","key":"5913_CR31","first-page":"1667","volume":"30","author":"L Benesova","year":"2010","unstructured":"Benesova L, Minarik M, Jancarikova D, Belsanova B, Pesek M. Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors. Anticancer Res. 2010;30(5):1667\u201371.","journal-title":"Anticancer Res"},{"issue":"3","key":"5913_CR32","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/JTO.0b013e3181cee47e","volume":"5","author":"M Takeda","year":"2010","unstructured":"Takeda M, Okamoto I, Fujita Y, Arao T, Ito H, Fukuoka M, et al. De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer. J Thorac Oncol. 2010;5(3):399\u2013400.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"5913_CR33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4132\/jptm.2016.03.09","volume":"50","author":"T Lee","year":"2016","unstructured":"Lee T, Lee B, Choi Y-L, Han J, Ahn M-J, Um S-W. Non-small cell lung cancer with concomitant EGFR, KRAS, and ALK mutation: clinicopathologic features of 12 cases. J Pathol Transl Med. 2016;50(3):197.","journal-title":"J Pathol Transl Med"},{"issue":"1","key":"5913_CR34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12943-018-0789-x","volume":"17","author":"M Rom\u00e1n","year":"2018","unstructured":"Rom\u00e1n M, Baraibar I, L\u00f3pez I, Nadal E, Rolfo C, Vicent S, et al. KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. Mol Cancer. 2018;17(1):33.","journal-title":"Mol Cancer"},{"issue":"1","key":"5913_CR35","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cancergen.2012.12.003","volume":"206","author":"O Fiala","year":"2013","unstructured":"Fiala O, Pesek M, Finek J, Benesova L, Belsanova B, Minarik M. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non\u2013small cell lung cancer. Cancer Genet. 2013;206(1):26\u201331.","journal-title":"Cancer Genet"},{"issue":"1","key":"5913_CR36","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.lungcan.2012.06.005","volume":"78","author":"G Metro","year":"2012","unstructured":"Metro G, Chiari R, Duranti S, Siggillino A, Fischer MJ, Giannarelli D, et al. Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype. Lung Cancer. 2012;78(1):81\u20136.","journal-title":"Lung Cancer"},{"key":"5913_CR37","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.2147\/OTT.S133082","volume":"10","author":"Y Liu","year":"2017","unstructured":"Liu Y, Sun L, Xiong Z-C, Sun X, Zhang S-L, Ma J-T, et al. Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs. Onco Targets Ther. 2017;10:2267.","journal-title":"Onco Targets Ther"},{"issue":"7","key":"5913_CR38","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1158\/1078-0432.CCR-13-2233","volume":"20","author":"C. Costa","year":"2014","unstructured":"Costa C, Molina-Vila MA, Drozdowskyj A, Gimenez-Capitan A, Bertran-Alamillo J, Karachaliou N, et al. The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin Cancer Res. 2014;20:2001-10.","journal-title":"Clinical Cancer Research"},{"issue":"18","key":"5913_CR39","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1002\/cncr.29493","volume":"121","author":"J Naidoo","year":"2015","unstructured":"Naidoo J, Sima CS, Rodriguez K, Busby N, Nafa K, Ladanyi M, et al. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: clinical outcomes and response to erlotinib. Cancer. 2015;121(18):3212\u201320.","journal-title":"Cancer"},{"issue":"2","key":"5913_CR40","doi-asserted-by":"publisher","first-page":"623","DOI":"10.4143\/crt.2018.151","volume":"51","author":"Seonggyu Byeon","year":"2019","unstructured":"Byeon S, Kim Y, Lim SW, Cho JH, Park S, Lee J, et al. Clinical outcomes of EGFR exon 20 insertion mutations in advanced non-small cell lung Cancer in Korea. Cancer Res Treat. 2019;51:623-31.","journal-title":"Cancer Research and Treatment"},{"issue":"3","key":"5913_CR41","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239\u201346.","journal-title":"Lancet Oncol"},{"issue":"14","key":"5913_CR42","doi-asserted-by":"publisher","first-page":"12783","DOI":"10.18632\/oncotarget.3727","volume":"6","author":"E Bria","year":"2015","unstructured":"Bria E, Pilotto S, Amato E, Fassan M, Novello S, Peretti U, et al. Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma. Oncotarget. 2015;6(14):12783.","journal-title":"Oncotarget"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5913-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5913-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5913-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T23:05:36Z","timestamp":1594854336000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5913-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,17]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5913"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5913-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,17]]},"assertion":[{"value":"19 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Given that this is a retrospective chart review study, we did not obtain written nor verbal informed consents from the patients in this study. The present study was approved by the Institutional Review Board of Siriraj Hospital, Mahidol University (reference number: 160\/2018).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"701"}}